Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine

The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2KMKedr
via IFTTT